October 2, 2017 — Reflow Medical Inc. announced that the company has received 510(k) clearance from the U.S. Food and Drug Administration (FDA) to market its Wingman14C Crossing Catheter for use in conjunction with a guidewire to access discrete regions of the coronary vasculature.

Medtronic plc recently announced a new post-market clinical study to evaluate its CoreValve Evolut Pro valve in everyday clinical practice. Studying patients with severe symptomatic aortic stenosis at an intermediate, high or extreme risk for open-heart surgery, the FORWARD PRO Clinical Study will evaluate longer-term performance (out to five years) of the next-generation self-expanding transcatheter aortic valve implantation (TAVI) system, which was recently approved for commercial use in Europe and United States.

October 2, 2017 — Boston Scientific announced a definitive agreement to acquire Apama Medical Inc., a privately-held company that is developing the Apama Radiofrequency (RF) Balloon Catheter System for the treatment of atrial fibrillation (AF). The deal calls for $175 million in cash up-front and a maximum of $125 million in contingent payments over the period of 2018-2020, based on achievements of clinical and regulatory milestones.

Abbott has pulled the Absorb Bioresorbable scaffold stent off the market.

October 2, 2017 — Here is the list of the most popular articles and videos on the Diagnostic and Interventional Cardiology (DAIC) magazine website from the month of September, based on website analytics of the month’s 126,393 pageviews:

Top Cardiology Technology Articles

1. Abbott Will End Sales of Absorb Bioresorbable Stent

September 29, 2017 — TherOx Inc. announced that the U.S. Food and Drug Administration (FDA) has accepted the premarket approval (PMA) application for its Supersaturated Oxygen (SSO2) Therapy system. The second-generation SSO2 Therapy system is designed to reduce infarct size and thereby improve outcomes in anterior acute myocardial infarction (AMI) patients treated within six hours of symptom onset.

Avinger Inc. recently announced Conformité Européenne (CE) Marking approval for treating in-stent restenosis with the Pantheris Lumivascular atherectomy system.

September 28, 2017 — New research revealed that on average, more than 75 percent of people aged 65 and older worldwide are not being screened for atrial fibrillation (AF) and other common stroke risk factors during routine primary care examinations, even though this population is at high risk for stroke.

World Heart Congress

The World Heart Congress meeting will be staffed with organizers with many professional attributes of great quality, and the selected venue will allow conference speakers and attendees opportunities to engage in collaborative efforts while learning more about some of the current trends and research practices applied to address factors relative to cardiovascular health.

Subscribe to
© Copyright Wainscot Media. All Rights Reserved.
Subscribe Now